Cirio advised Intervacc on the deal.
Intervacc AB has entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC to commercialize Intervacc’s leading vaccine candidate Strangvac® in Europe, excluding the Nordic and Baltic countries.
Strangvac® is in late-stage regulatory review with the European Medicines Agency and is an innovative vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. The distribution agreement is based on a transfer price plus additional future payments linked to pre-defined sales milestones.
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company’s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB.
Dechra is a global specialist veterinary pharmaceuticals and related products business. The majority of Dechra’s products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
Cirio’s team consisted of Anders Burén (Picture), Ulrica Salomon and Anna Hovstadius.
Law Firms: Cirio Law Firm;
Clients: Intervacc ;